BPC-157 Mechanism of Action — Angiogenesis, NO Pathway &

*Proposed mechanisms of stable gastric pentadecapeptide BPC-157: VEGFR2 phosphorylation, nitric oxide pathway modulation, growth-factor crosstalk and gastrointestinal cytoprotection.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use.

Overview

BPC-157 (Body Protection Compound) is a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice. Its proposed mechanisms have been mapped largely by the Sikirić group across more than 100 rodent studies.

Angiogenesis — VEGFR2 Pathway

BPC-157 upregulates VEGFR2 expression and phosphorylation in endothelial cells, driving angiogenesis without requiring exogenous VEGF. Tube-formation assays and in vivo wound-healing models consistently show accelerated capillary network formation.

Nitric Oxide System Modulation

BPC-157 interacts with the NO system, increasing NO synthesis in damaged tissues and counteracting the gastric damage produced by L-NAME (a NOS inhibitor). NO-system modulation is proposed as the unifying mechanism behind its diverse organ-protective effects.

Growth-Factor Crosstalk

• Upregulation of growth hormone receptor expression in tendon fibroblasts
• Modulation of EGF receptor and FGF receptor expression in wound-bed fibroblasts
• Activation of FAK / paxillin signalling in fibroblast adhesion

Gastrointestinal Cytoprotection

BPC-157 protects gastric mucosa against NSAID-, ethanol- and stress-induced injury; accelerates healing of cysteamine-induced duodenal ulcers; and restores blood flow in models of intestinal anastomosis. These effects underpin the name "Body Protection Compound."

Tendon, Ligament & Bone

Rodent transected-Achilles models show dose-dependent acceleration of tenocyte proliferation and collagen organisation under BPC-157 treatment. Comparable effects have been reported in medial collateral ligament transection and bone-fracture models.

Routes & Bioavailability

Stable in gastric juice — oral, SC and IP routes all show preclinical activity. No standardised human pharmacokinetic profile has been published.

Frequently Asked Research Questions

What is the primary proposed mechanism of BPC-157?

Angiogenesis driven by VEGFR2 upregulation and nitric oxide system modulation are the most consistently reported mechanisms across the published preclinical literature.

Does BPC-157 work without VEGF?

Cell-based tube-formation assays show BPC-157 promotes capillary-like network formation in endothelial cells independent of exogenous VEGF, suggesting direct receptor-level activity at VEGFR2.

Why is it called 'Body Protection Compound'?

The peptide was originally isolated from human gastric juice for its ability to protect gastric mucosa against multiple injury models. Subsequent preclinical work extended the protective profile to tendon, ligament, bone, liver and brain models.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Coskun T, et al. *LY3298176 (tirzepatide) — discovery of a dual GIP/GLP-1 agonist.* Mol Metab. 2018.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC-157.* Curr Pharm Des. 2018.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Falutz J, et al. *Tesamorelin in HIV-associated lipodystrophy.* N Engl J Med. 2007.

1. Pfaus JG, et al. *Bremelanotide — central melanocortin agonism.* Curr Sex Health Rep. 2007.

1. Khavinson VK, et al. *Epitalon — pineal-tetrapeptide telomerase activation.* Bull Exp Biol Med. 2003.

1. Imai S, Guarente L. *NAD+ and sirtuins in aging and disease.* Trends Cell Biol. 2014.